We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Advanced Oncotherapy Plc | LSE:AVO | London | Ordinary Share | GB00BD6SX109 | ORD 25P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 1.925 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Medical Laboratories | 0 | -29.49M | -0.0549 | -0.35 | 10.32M |
TIDMAVO
RNS Number : 1103C
Advanced Oncotherapy PLC
11 April 2017
11 April 2017
ADVANCED ONCOTHERAPY PLC
("Advanced Oncotherapy" or the "Company")
Conversion of Convertible Loan Notes
Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that Bracknor Investment Group ("Bracknor") has advised the Company that they will convert a portion of the first tranche of the Convertible Loan Notes ("CLN") issued to them on 22 February 2017 into new ordinary shares of 25p each in the share capital of the Company ("Ordinary Shares"). Further details of the conversion are set out below.
Number of CLN converted: 10 Total nominal value of the CLN converted: GBP100,000 Conversion price: GBP0.2789 Number of shares issued from the conversion: 358,551 Shares issued for the satisfaction of the conversion fees: 10,756
Application will be made for admission to trading on AIM ("Admission") of the 369,307 new Ordinary Shares deriving from the conversion of the CLN and in satisfaction of the conversion fees and it is expected that Admission will occur on or around 18 April 2017.
Total voting rights
Following Admission, the Company's enlarged issued share capital will comprise 73,385,807 Ordinary Shares, with voting rights. The Company does not hold any Ordinary Shares in treasury. Therefore the total number of Ordinary Shares in the Company with voting rights will be 73,385,807. This figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.
Advanced Oncotherapy Plc www.avoplc.com Dr. Michael Sinclair, Tel: +44 20 3617 8728 Executive Chairman Nicolas Serandour, CEO Stockdale Securities (Nomad & Joint Broker) Antonio Bossi / David Tel: +44 20 7601 6100 Coaten Stifel Nicolaus Europe (Joint Broker) Jonathan Senior / Ben Tel: +44 20 7710 7600 Maddison Walbrook PR (Financial Tel: +44 20 7933 8780 or PR & IR) avo@walbrookpr.com Paul McManus / Anna Dunphy Mob: +44 7980 541 893 / Mob: +44 7876 741 001
About Advanced Oncotherapy Plc www.avoplc.com
Advanced Oncotherapy is a provider of particle therapy with protons that harnesses the best in modern technology. Advanced Oncotherapy's team "ADAM", based in Geneva, focuses on the development of a proprietary proton accelerator called Linac Image Guided Hadron Technology (LIGHT). LIGHT accelerates protons to the energy levels achieved in legacy machines but in a unit that is a quarter of the size and between a quarter and a fifth of the cost. This compact configuration delivers proton beams in a way that facilitates greater precision and electronic control which is not achievable with older technologies.
Advanced Oncotherapy will offer healthcare providers affordable systems that will enable them to treat cancer with an innovative technology as well as better health outcomes and lower treatment related side effects.
Advanced Oncotherapy continually monitors the market for any emerging improvements in delivering proton therapy and actively seeks working relationships with providers of these innovative technologies. Through these relationships, the Company will remain the prime provider of an innovative and cost-effective system for particle therapy with protons.
This information is provided by RNS
The company news service from the London Stock Exchange
END
CONLLFFESTIILID
(END) Dow Jones Newswires
April 11, 2017 02:00 ET (06:00 GMT)
1 Year Advanced Oncotherapy Chart |
1 Month Advanced Oncotherapy Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions